Core Insights - Globalization remains the main theme for the medical device industry in 2025, with Yejun Medical leading in the cardiovascular intervention sector, achieving an overseas revenue share of 88.4% across over 70 countries and regions [1][3] - The company's mid-year report shows robust growth in both revenue and net profit, validating its "globalization + innovation" dual-driven strategy, and the announcement of a special dividend reflects management's optimistic outlook [1][3][4] - The capital market has responded positively, with the company's stock price increasing by 35.89% year-to-date as of August 15 [1] Financial Performance - In the first half of 2025, Yejun Medical reported total revenue of $83.55 million, a year-on-year increase of 5.9%, with product sales volume reaching 91,900 units, including 77,900 units of proprietary products, which saw an 8.6% increase [3][4] - The net profit attributable to shareholders reached $19.80 million, up 5.1%, with core operating profit increasing by 11.4% to $15.10 million, and basic earnings per share rose by 5.26% to $0.024 [3][4] - The board proposed a special dividend of HKD 0.15 per share, in addition to a previously declared final dividend of HKD 0.10 per share, totaling HKD 0.25 per share for the year [3] Cash Flow Management - As of June 30, 2025, the company had cash and bank balances of $237 million, providing a solid financial safety net for R&D, product commercialization, global acquisitions, and key capacity construction [4] Strategic Pillars for Growth - Yejun Medical focuses on three strategic pillars: regional deepening, innovative mergers and acquisitions, and capacity building [5] - The Asia-Pacific region is the largest contributor to revenue, generating $27.31 million, a 14% increase year-on-year, with strong performance in Indonesia and accelerated sales in Singapore and Malaysia [5][6] - In Europe, the Middle East, and Africa, revenue grew by 17% to $22.43 million, driven by strong sales of proprietary balloon products in direct sales markets like Germany, France, and Spain [5][6] Product Strategy - The company employs a multi-faceted expansion strategy through innovation, mergers, and collaborations, enhancing its competitive moat [7] - As of mid-2025, Yejun Medical holds over 250 authorized patents and has received multiple key product certifications, increasing its approved product count to over 55 [7] - The company is actively pursuing new product registrations and has several products in clinical trials, including the Sapphire 3 coronary balloon [7] Production and Supply Chain - Yejun Medical is accelerating capacity construction and strengthening supply chain management, with production bases in Shenzhen, the Netherlands, and Germany, achieving an annual capacity of approximately 2.1 million units [9] - The new R&D and production base in Hangzhou is expected to be operational by 2027, adding an annual capacity of 2.4 million units, which will enhance cost advantages and support sustainable commercialization [9] Future Outlook - Several catalysts are expected to positively impact the company in the short term, including easing U.S. tariffs, the launch of high-end products in Japan, and the establishment of new direct sales teams in Europe [10] - The company's long-term growth path is clear, with plans to participate in volume-based procurement in China and the upcoming launch of self-developed products [10][11] - The company's intrinsic value is not fully reflected in the market, with a PE ratio of 13.174, indicating significant upside potential [10]

Core Viewpoint - Globalization remains the main theme for the medical device industry in 2025, with the company Yejuy Medical leading in the cardiovascular intervention field through a proactive global strategy, achieving an overseas revenue share of 88.4% [1][3]. Financial Performance - In the first half of 2025, the company reported total revenue of $83.55 million, a year-on-year increase of 5.9%, with product sales reaching 91,900 units, including 77,900 units of proprietary products, which saw an 8.6% increase [3][4]. - The net profit attributable to shareholders was $19.80 million, up 5.1%, while core operating profit reached $15.10 million, growing by 11.4% [3][4]. - The company announced a special dividend of 15 HKD per share, in addition to a previously declared dividend of 10 HKD per share, totaling 25 HKD per share for the year, reflecting management's confidence in long-term prospects [3][4]. Cash Flow Management - As of June 30, 2025, the company had cash and bank balances of $237 million, providing a solid financial safety net for R&D, product commercialization, global acquisitions, and capacity building [4][9]. Strategic Pillars for Growth - The company focuses on three strategic pillars: regional deepening, innovation and acquisitions, and capacity building [4][9]. - The Asia-Pacific region contributed $27.31 million in revenue, a 14% increase, with Indonesia showing significant growth [5][6]. - In Europe, the Middle East, and Africa, revenue grew by 17% to $22.43 million, driven by strong sales of proprietary balloon products [5][6]. Product Strategy - The company has over 250 authorized patents and has successfully obtained multiple product certifications, expanding its product portfolio [7][8]. - New product registrations and clinical trials are ongoing, with several products expected to launch globally in the coming years [7][8]. Production and Supply Chain - The company has established production bases in Shenzhen, the Netherlands, and Germany, with an annual capacity of approximately 2.1 million units, and a new facility in Hangzhou expected to add 2.4 million units by 2027 [9]. Market Outlook - Short-term catalysts include easing U.S. tariffs, the launch of high-end products in Japan, and the establishment of new direct sales teams in Europe [10]. - Long-term growth is supported by participation in volume-based procurement in China, the launch of self-developed products, and rising demand in emerging markets [10][11]. Market Valuation - The company's PE ratio as of August 15 was 13.174, indicating potential for upward growth compared to historical levels [11][13].

Core Insights - The company reported a revenue of $83.6 million for the six months ending June 30, 2025, representing a 5.9% increase year-on-year [1] - Core operating profit increased by 11.4% to $15.1 million, while profit attributable to shareholders rose by 5.1% to $19.8 million [1] - The company declared a special cash dividend of HKD 0.15 per ordinary share, celebrating its 25th anniversary, alongside a final dividend of HKD 0.10 per share paid on June 16, 2025, totaling HKD 0.25 per share for 2025 [1] Financial Performance - Revenue growth was driven by strong performance in the U.S. market and contributions from emerging markets in the Asia-Pacific, Europe, the Middle East, and Africa [1][2] - The company maintained a robust financial position with cash and bank balances reaching $237.1 million as of June 30, 2025 [1] Strategic Outlook - The CEO emphasized the company's commitment to innovation and global commercialization, which has established a strong reputation and resilience through various economic cycles [2] - The company aims to enhance brand value and competitive advantage through direct sales coverage, excellent sales support, investment in innovation, and a comprehensive range of PCI and PTA products [2]

Core Viewpoint - The company reported a revenue of $83.55 million for the six months ending June 30, 2025, reflecting a year-on-year increase of 5.88% and a profit attributable to shareholders of $19.785 million, up 5.08% year-on-year, with a proposed special dividend of HK$0.15 (approximately $0.0192) per share [1] Group 1 - The company achieved strong year-on-year growth in the U.S. market despite tariff disruptions, indicating robust demand for its quality products [1] - Emerging markets, particularly in the Asia-Pacific and Europe, Middle East, and Africa regions, have become the main growth engines for the first half of the year due to ongoing socio-economic development [1] - The growth was partially offset by a decrease in sales in the Japanese market and a decline in average selling prices in the Chinese market [1] Group 2 - The increase in net profit was primarily driven by foreign exchange gains and reduced income tax expenses, although it was offset by decreased interest income and increased selling and marketing expenses [1]

Core Viewpoint - Yiju Medical (06929) reported a revenue of $83.55 million for the six months ending June 30, 2025, representing a year-on-year increase of 5.88% [1] - The profit attributable to shareholders for the period was $19.785 million, an increase of 5.08% year-on-year, with basic earnings per share at 2.4 cents [1] - The company proposed a special dividend of 15 Hong Kong cents (approximately 1.92 US cents) per share [1] Group Performance - Despite tariff disruptions, the company achieved strong year-on-year growth in the U.S. market, indicating robust demand for its quality products [1] - Emerging markets, particularly in the Asia-Pacific region and Europe, the Middle East, and Africa, have shown positive trends, becoming the main growth engines in the first half of the year [1] - However, the growth was partially offset by a decrease in sales in the Japanese market and a decline in average selling prices in the Chinese market [1] Financial Analysis - The net profit growth was primarily driven by an increase in foreign exchange gains and a reduction in income tax expenses [1] - This growth was partially countered by a decrease in interest income and an increase in sales and marketing expenses [1]

Core Viewpoint - The company Yiju Medical (06929) announced a special dividend of HKD 0.15 per share, to be distributed on October 6, 2025 [1] Group 1 - The special dividend reflects the company's commitment to returning value to shareholders [1] - The announcement indicates the company's financial health and ability to generate cash flow [1]

Core Viewpoint - Yiju Medical (06929) announced a special dividend of HKD 0.15 per share to be distributed on October 6, 2025 [1] Company Summary - The company is set to distribute a special dividend, indicating a positive cash flow situation and potential shareholder value enhancement [1]

發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，董事會包括執行董事錢永勛先生、劉桂禎女士及陳泳成先生；非執行董事梁鼎新先生及周伊博士；以及獨立非執行 董事陳業強先生、樓家強先生BBS、MH、JP及譚麗芬醫生。 第 2 頁 共 2 頁 v 1.1.1 第 1 頁 共 2 頁 v 1.1.1 EF001 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 業聚醫療集團控股有限公司 | | 股份代號 | 06929 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 宣派特別股息及暫停辦理股份過戶登記手續 | | 公告日期 | 2025年8月15日 | | 公告狀態 | 新公告 | | 股息信息 | | | ...

Financial Performance - Revenue for the six months ended June 30, 2025, was $83,550,000, representing a 5.9% increase compared to $78,910,000 for the same period in 2024[4] - Gross profit for the same period was $55,897,000, slightly up by 0.2% from $55,776,000 in 2024[4] - Profit attributable to owners of the company increased by 5.1% to $19,785,000 from $18,828,000 year-over-year[4] - Basic and diluted earnings per share rose to 2.40 cents, a 5.3% increase from 2.28 cents in the previous year[4] - Operating profit for the period was $16,833,000, an increase from $15,871,000 in the prior year[5] - Total comprehensive income for the period was $25,635,000, compared to $14,871,000 in 2024[6] - Revenue for the six months ended June 30, 2025, was $83,550 thousand, an increase from $78,910 thousand for the same period in 2024, representing a growth of approximately 2.0%[17] - The cost of goods sold for the six months ended June 30, 2025, was $14,857 thousand, an increase from $12,288 thousand in 2024, representing a rise of about 20.9%[22] - The income tax expense for the six months ended June 30, 2025, was $3,322 thousand, compared to $2,103 thousand in 2024, reflecting an increase of approximately 58.0%[23] - Employee benefits expenses increased to $30,959 thousand for the six months ended June 30, 2025, compared to $29,043 thousand in 2024, marking an increase of about 6.6%[22] - The depreciation of property, plant, and equipment for the six months ended June 30, 2025, was $1,212 thousand, up from $1,003 thousand in 2024, indicating a growth of approximately 20.8%[22] - The group recorded a net foreign exchange gain of $1.5 million for the six months ended June 30, 2025, compared to a net loss of $0.7 million for the same period in 2024[81] - Net income attributable to the company's owners increased by 5.1% from $18.8 million to $19.8 million, driven by increased foreign exchange gains and reduced tax expenses[75] Assets and Liabilities - Non-current assets increased to $82,543,000 from $69,553,000 as of December 31, 2024[7] - Current assets totaled $363,259,000, slightly up from $361,457,000 at the end of 2024[7] - Total liabilities decreased to $35,819,000 from $36,633,000 in the previous year[8] - Cash and bank balances decreased from $248.6 million as of December 31, 2024, to $237.1 million as of June 30, 2025, primarily due to dividend payments of $10.6 million[77] - The current ratio was approximately 12.2 times as of June 30, 2025, compared to 11.8 times as of December 31, 2024[78] - The net current asset value increased by 0.8% from $330.7 million as of December 31, 2024, to $333.5 million as of June 30, 2025[79] Revenue Breakdown - Revenue from external customers in the Asia-Pacific region was $27,311 thousand for the six months ended June 30, 2025, compared to $23,955 thousand in 2024, reflecting a growth of about 14.0%[18] - Revenue from the Asia-Pacific region increased significantly to $27.3 million, a year-on-year growth of 14.0%[44] - Revenue from Europe, the Middle East, and Africa rose by 17.0% to $22.4 million, driven by sales growth of proprietary balloon products in direct and distribution markets[45] - Revenue from Japan decreased by 14.8% to $16.1 million due to a shift in sales strategy, although marketing expenses were significantly reduced[46] - Revenue from the U.S. market increased by 20.0% to $8.0 million, attributed to significant sales growth of coronary and peripheral balloons[48] - Revenue from third-party products increased by 20.6% to $4.6 million, driven by sales growth in Indonesia[61] Corporate Governance and Compliance - The company is focused on compliance with the corporate governance code as per the listing rules, ensuring transparency and accountability[101] - The independent auditor has conducted a review of the interim financial data in accordance with the relevant standards, ensuring the integrity of the financial reporting[98] - The company is committed to adhering to the regulations set forth by the Hong Kong Stock Exchange and other applicable laws, reinforcing its operational legitimacy[101] Future Plans and Developments - The company plans to adopt new accounting standards effective January 1, 2026, which are not expected to have a significant impact on the financial position or performance[15] - The company plans to accelerate product registration in Taiwan following the acquisition of a local distributor, aiming to expand its product portfolio[57] - The company expects the new generation Scoreflex QUAD balloon to launch in Q4 2025, which is anticipated to reverse the revenue decline in the Japanese market[57] - The company is constructing its largest R&D and manufacturing facility in Hangzhou, China, expected to be operational by 2027, increasing annual production capacity by approximately 2.4 million units[55] - The group plans to utilize the net proceeds from the global offering for ongoing product development and capacity expansion, with a total expected use of $31.6 million[90] Employee and Talent Management - The group employed 1,432 employees as of June 30, 2025, with employee benefit expenses amounting to approximately $31.0 million for the six months ended June 30, 2025, compared to $29.0 million for the same period in 2024[89] - The company has adopted various incentive plans, including stock option plans and share reward plans, to motivate and retain talent[103] Dividends - The company declared a final dividend of HKD 0.10 per share (approximately USD 0.0128), totaling about USD 10.61 million for the year ending December 31, 2024[30] - The board declared a special dividend of HKD 0.15 per ordinary share, payable on October 6, 2025, in addition to a previously declared final dividend of HKD 0.10 per ordinary share[91]

Core Viewpoint - The company, Aiyu Medical (06929.HK), has scheduled a board meeting on August 15, 2025, to consider and approve its interim results for the period ending June 30, 2025, and to discuss the potential distribution of an interim dividend, among other matters [1] Group 1 - The board meeting is set for August 15, 2025 [1] - The meeting will address the approval of interim results for the six months ending June 30, 2025 [1] - The company will consider the distribution of an interim dividend, if applicable [1]